+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID04486833

Study of Quaratusugene Ozeplasmid Combined With Osimertinib Versus Platinum Chemotherapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer

Led by Genprex, Inc. · Updated on 2026-09-16

158

Participants Needed

10

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of quaratusugene ozeplasmid Reqorsa combined with osimertinib in patients with advanced metastatic or recurrent non-small cell lung cancer NSCLC that has specific EGFR mutations and has worsened despite osimertinib treatment. This study includes a Phase 1 dose escalation portion and two Phase 2 parts to assess treatment safety and tumor response. It is an open-label, multi-center, randomized trial comparing the investigational combination therapy against platinum-based chemotherapy. Participants in Phase 1 and Phase 2a receive quaratusugene ozeplasmid intravenously every 21 days plus daily oral osimertinib at a fixed 80 mg dose in 21-day cycles until disease progression or unacceptable side effects. In Phase 2b, patients are randomly assigned to either the combination therapy or platinum-based chemotherapy, continuing treatment until progression or intolerable toxicity. Some patients may also receive local therapies like radiation before enrollment. Throughout the study, participants undergo regular safety assessments including monitoring for adverse events and dose-limiting toxicities. Researchers evaluate outcomes such as the recommended dose, overall response rate, progression-free survival, duration of response, pharmacokinetics, and overall survival at specified intervals. The trial involves ongoing clinical evaluations, laboratory tests, tumor biopsies, and imaging to track disease status and treatment effects over several months to years.

CONDITIONS

Brief Title

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Research Team

S

Sr Director, Clinical Operations

C

Chief Medical Officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here